Journal of inflammation research · 2025
Dupilumab-Induced Generalized Lichen Planus: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feng Hui-Shang, Zhang Chuang, Guo Yang, Jia Yuan-Ning, Zhai Ye, Zheng Xiao-Ran, Zhang Tai, Zhu Bao-Chen, Zhang Wan-Tong, Hua Guo-Dong
Аннотация
BACKGROUND: Lichen planus (LP) is a chronic inflammatory skin disease of unknown cause. Common subtypes include generalized LP, linear LP, annular LP, and hypertrophic LP. Current clinical evidence suggests that lichen planus is a T-cell-mediated autoimmune disorder. Therefore, an increasing number of clinicians are opting for biologics or immunomodulators to manage lichen planus, but the reported evidence on their efficacy and safety remains limited.
CASE SUMMARY: This case report describes a 32-year-old female with pre-existing localized lichen planus (LP) who developed generalized LP after IL-4Rα inhibitor dupilumab therapy. Following three dupilumab injections, progressive dissemination of pruritic pink-to-flesh-coloured or light-brown papules to the trunk and limbs was observed. The lesions regressed upon dupilumab discontinuation and pharmacological intervention. Diagnosis was confirmed by dermoscopy and histopathology.
CONCLUSION: A temporal correlation and Naranjo adverse drug reaction score of 8 indicated dupilumab as the trigger, likely via Th1/Th2 immune deviation. This first-documented paradoxical reaction underscores dupilumab's potential to trigger generalized LP through immune deviation.
CASE SUMMARY: This case report describes a 32-year-old female with pre-existing localized lichen planus (LP) who developed generalized LP after IL-4Rα inhibitor dupilumab therapy. Following three dupilumab injections, progressive dissemination of pruritic pink-to-flesh-coloured or light-brown papules to the trunk and limbs was observed. The lesions regressed upon dupilumab discontinuation and pharmacological intervention. Diagnosis was confirmed by dermoscopy and histopathology.
CONCLUSION: A temporal correlation and Naranjo adverse drug reaction score of 8 indicated dupilumab as the trigger, likely via Th1/Th2 immune deviation. This first-documented paradoxical reaction underscores dupilumab's potential to trigger generalized LP through immune deviation.